Biofidelity raises $24 million in financing to accelerate commercialization and expand product pipeline.

Apr 03, 2024•over 1 year ago

Amount Raised

$24 Million

CambridgeHealth Care

Investors

Longwall VenturesBlue Yard CapitalOctopus VenturesAgilent Technologies

Description

Biofidelity successfully completed a financing round totalling $24 million, which will accelerate the growth of the Company, including commercial and clinical expansion, and enable the establishment of a dedicated manufacturing facility in the United Kingdom.

Company Information

Company

Biofidelity

Location

Cambridge, Massachusetts, United States

About

Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world. We have launched our first product, ASPYRE-Lung, in the US and we have an extensive pipeline of novel products. Biofidelity has developed a novel molecular biology technology which enables genomic analysis for cancer diagnosis to be carried out locally, quickly and far more cost-effectively.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends